key: cord-0019556-yhvgxqf4
authors: Brabrand, Mikkel; Kellett, John; Nickel, Christian H.
title: The Reply
date: 2021-07-30
journal: Am J Med
DOI: 10.1016/j.amjmed.2021.03.019
sha: b26bd6f821443b6bc26d14c18c034a1efdc30b83
doc_id: 19556
cord_uid: yhvgxqf4

nan

We thank Dr Zalmay et al for giving us the opportunity to respond to their concerns. The aim of our study 1 was to examine the diagnoses and outcomes of acute medical patients with an elevated D-dimer. Our results confirm that patients with normal D-dimer levels are unlikely to die within 90 days, and that elevated D-dimer levels are not only associated with an increased risk for venous thromboembolism, but are also associated with infection, cancer, heart failure, and anemia. Our results confirm that D-dimer is a nonspecific test, and therefore, is of little diagnostic value in an unselected patient population, but is of prognostic value. This leads us to speculate, but not conclude, that D-dimer could be used as a prognostic marker. The main concern against routine measurement of D-dimers on every emergency department patient is that it would result in superfluous downstream investigations. However, in an observational trial during the current COVID-19 pandemic, in which a third of Danish emergency departments participated, routine measurement of D-dimers in more than 500,000 visits did not result in increased unnecessary radiological investigations. 2 We, of course, agree with Zalmay et al that the jury is still out on routine use of the D-dimer in acute medical illness, and that large multicenter trials will be needed to prove that routine D-dimer measurement leads to improved outcomes.

The diagnoses and outcomes of emergency patients with an elevated D-dimer over the next 90 days

Routine measurement of d-dimers on suspected SARS-CoV2-infected patients does not lead to significant increase in radiological investigations